The Newer Diabetes Drugs and Patients with NASH

S2-E7 – The Newer Diabetes Drugs and Patients with NASH

Jörn Schattenberg and Fatty Liver Foundation President Wayne Eskridge join Louise and Roger to consider the current and future roles that GLP-1 receptor agonists like semaglutide and SGLT-2 inhibitors like Jardiance in treating NASH patients.
()

Over the next couple of years, we are likely to see improvements in our ability to diagnose and track NASH patients but no new medicines to treat them. On this podcast, Jörn Schattenberg reviews data on the role that two relatively recent classes of diabetes drugs, GLP-1s (semaglutide) and SGLT-2s (Jardiance), can play in NASH and NAFLD therapy. Wayne Eskridge discusses implications for patients. while Louise Campbell and Roger Green elaborate opportunities and challenges in educating patients and health care professionals to think about liver and diabetes in a more integrated way. This episode presents perspectives and concepts with value today.

How useful was this post?

Click on a star to rate it!

Average rating / 5. Vote count:

No votes so far! Be the first to rate this post.

Request A Transcript of This Episode
Request Transcript
First
Last

Ask Our Panelists A Question…

Podcast Quesitonaire
Is your question directed towards one of our panelists?

If your question is answered in our next Podcast, would you like be tagged?

Advance Notification

We send out emails to notify our followers before we post on social media, and often it's before your podcast app is updated!